Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio's Approved Drugs Database

Kepivance

Palifermin

Download PDF containing detailed information. PDF Version

Image Results

Press Releases About Kepivance:
Emerging oncology treatments: A focus on targeted therapeutics,	1st June, 2006	Dailyupdates	Emerging oncology treatments: A focus on targeted therapeutics, supergeneric reformulations and supportive care Feb, 2005 Leaddiscovery: The oncology market is the third largest

Companies working in the area of Kepivance from Bioportfolio's Biocorporate database :
Company Name
Kepivance™ (palifermin) Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with... www.kepivance.com View full profile

This page has been viewed 46 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Kepivance across BioPortfolio, or for Kepivance Research Reports

Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

BioPortfolio's Approved Drugs Database

Kepivance

Palifermin

Image Results

Press Releases About Kepivance:

Companies working in the area of Kepivance from Bioportfolio's Biocorporate database :

Kepivance™ (palifermin)